Novo Nordisk | NVO - Pre Tax Profit


Novo Nordisk reported DKK62.17B in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
ANI Pharmaceuticals USD 40.22M 8.74M Mar/2026
Aurora Cannabis CAD 11.41M 12.99M Mar/2026
Bausch Health Companies USD 348M 1.7B Jun/2026
Bristol-Myers Squibb USD 4.99B 1.75B Jun/2026
Canopy Growth CAD -157.96M 95.71M Mar/2026
Corcept Therapeutics USD -44.72M 54.62M Mar/2026
Drreddys Laboratories INR 2B 13.43B Mar/2026
Eli Lilly USD 8.85B 583.8M Mar/2026
GlaxoSmithKline GBP 2.68B 532M Jun/2026
Merck USD -3.53B 6.95B Mar/2026
Nektar Therapeutics USD -43.09M 8.39M Mar/2026
Novartis USD 4.27B 430M Jun/2026
Novo Nordisk DKK 33.8B 3.23B Jun/2025
Novo Nordisk DKK 62.17B 36.66B Mar/2026
Pacira USD 5M 4.43M Mar/2026
Perrigo USD 105.4M 513.9M Jun/2026
Phibro Animal Health USD 38.62M 1.26M Dec/2025
Prestige Brands USD 64.77M 2.96M Mar/2026
Sanofi EUR 837M 1.17B Jun/2026
Supernus Pharmaceuticals USD -57.65M 51.7M Jun/2026
Zoetis USD 758M 3M Mar/2026